Hyogo-ken, Japan

Yohsuke Ohta


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:

goldMedal1 out of 8 
 
International Reagents Corporation
 patents
silverMedal1 out of 832,761 
Other
 patents
where one patent can have more than one assignee

Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Yohsuke Ohta

Introduction

Yohsuke Ohta is a notable inventor based in Hyogo-ken, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for various medical applications, showcasing the importance of innovation in healthcare.

Latest Patents

Yohsuke Ohta holds a patent for "Anti-annexin-V monoclonal antibodies, and preparation and use thereof." This patent highlights his expertise in creating antibodies that can be utilized in therapeutic and diagnostic applications. The innovation represented by this patent is a testament to his commitment to advancing medical science.

Career Highlights

Throughout his career, Ohta has worked with various organizations, including International Reagents Corporation. His experience in these companies has allowed him to refine his skills and contribute to important projects in the field of biotechnology. His work has been instrumental in pushing the boundaries of what is possible in medical research.

Collaborations

Ohta has collaborated with notable colleagues such as Noboru Kaneko and Ryuko Matsuda. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and innovation.

Conclusion

Yohsuke Ohta's contributions to the field of biotechnology through his patent and collaborations demonstrate the vital role of inventors in advancing medical science. His work continues to inspire future innovations in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…